TY - JOUR
T1 - Minority HIV patients' perceptions of barriers and facilitators to participation in clinical research
AU - Wolak, Caitlin
AU - Bass, Sarah B.
AU - Tedaldi, Ellen
AU - Vandenburg-Wolf, Mary
AU - Rohrer, Caitlin
PY - 2012/6
Y1 - 2012/6
N2 - HIV clinical trials play an essential role in producing new HIV medications, developing guidelines for the appropriate timing of antiretroviral treatment, and evaluating behavioral interventions that aim to increase the quality of life of HIV-infected individuals. It is critical to have participation from all demographic groups, yet minorities are disproportionately underrepresented in HIV clinical research. This study assessed HIV+ minority patient perceptions of the barriers and benefits of participating in HIV clinical trials in an HIV clinic of a large, urban teaching hospital. Twentysix, age-eligible (18-65), minority patients were recruited and participated in three focus groups, separated by clinical research participation status. Results suggest differences in perceptions between those who had and had not participated. Facilitators for those who had participated included doctor recommendation and receiving extra medical attention. Those who had not participated indicated disclosure of HIV status, fear of losing the stability that their current medication regimen provided, distrust of the medical system and doubt about the origin of HIV were major deterrents of participation. Both groups indicated a need to better educate minority patients about what clinical research is and its benefits. To increase minority participation, it is vital to examine the perceptions of minority HIV-infected patients and develop culturally competent, developmentally appropriate messages that address these barriers.
AB - HIV clinical trials play an essential role in producing new HIV medications, developing guidelines for the appropriate timing of antiretroviral treatment, and evaluating behavioral interventions that aim to increase the quality of life of HIV-infected individuals. It is critical to have participation from all demographic groups, yet minorities are disproportionately underrepresented in HIV clinical research. This study assessed HIV+ minority patient perceptions of the barriers and benefits of participating in HIV clinical trials in an HIV clinic of a large, urban teaching hospital. Twentysix, age-eligible (18-65), minority patients were recruited and participated in three focus groups, separated by clinical research participation status. Results suggest differences in perceptions between those who had and had not participated. Facilitators for those who had participated included doctor recommendation and receiving extra medical attention. Those who had not participated indicated disclosure of HIV status, fear of losing the stability that their current medication regimen provided, distrust of the medical system and doubt about the origin of HIV were major deterrents of participation. Both groups indicated a need to better educate minority patients about what clinical research is and its benefits. To increase minority participation, it is vital to examine the perceptions of minority HIV-infected patients and develop culturally competent, developmentally appropriate messages that address these barriers.
KW - Acquired Immunodeficiency Syndrome/epidemiology
KW - Adolescent
KW - Adult
KW - Aged
KW - Clinical Trials as Topic
KW - Communication Barriers
KW - Female
KW - Focus Groups
KW - HIV Seropositivity/epidemiology
KW - Humans
KW - Male
KW - Middle Aged
KW - Minority Groups
KW - Patient Selection
KW - Surveys and Questionnaires
KW - United States/epidemiology
KW - Young Adult
UR - http://www.scopus.com/inward/record.url?scp=84862603805&partnerID=8YFLogxK
UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=purepublist2023&SrcAuth=WosAPI&KeyUT=WOS:000308003000012&DestLinkType=FullRecord&DestApp=WOS
U2 - 10.2174/157016212800792531
DO - 10.2174/157016212800792531
M3 - Article
C2 - 22591357
SN - 1570-162X
VL - 10
SP - 348
EP - 355
JO - Current HIV Research
JF - Current HIV Research
IS - 4
ER -